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Rapidly Destructive Staphylococcus epidermidis 
Endocarditis
A.S. Zinkernagel, R.F. Speck, C. Ruef, W. Zingg, B. Berger-Bachi, B. Springer
Abstract
A 29-year-old man with rapidly destructive Staphylococcus 
epidermidis endocarditis after mitral valve reconstruction is 
presented. Resistance to rifampin and teicoplanin occurred 
during antibiotic treatment resulting in clinical failure and 
valve destruction. Subsequently, the patient was successfully 
treated, by combining valve replacement with antibiotic 
therapy including quinupristin/dalfopristin, levofloxacin, and 
vancomycin. In conclusion, S. epidermidis can cause rapid 
valve destruction with large vegetations, and combination of 
surgery and antibiotic therapy may be necessary.
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Introduction
Coagulase-negative staphylococci (CoNS) are part of nor-
mal human skin flora. Defining their clinical relevance 
in clinical samples poses a major diagnostic challenge. 
Notably, CoNS such as Staphylococcus epidermidis have 
emerged as a major cause of infection, particularly in hos-
pitalized patients with prosthetic heart valves, joint pros-
theses or indwelling catheters.
CoNS have the unique property to attach to matrix pro-
teins formed on polymer surfaces of foreign bodies. CoNS 
may generate a biofilm resulting eventually in multilayered 
biofilms. The importance of CoNS in foreign body infec-
tions is highlighted by the fact that they are responsible for 
over 50% of all cases of prosthetic valve endocarditis. Only 
1–5% of all native valve endocarditis are caused by CoNS 
[1]. The low virulence of CoNS may explain the typically 
subacute or even chronic course of infection. So far Staphy-
lococcus lugdunensis was thought to be the only CoNS spe-
cies known to cause rapidly progressive endocarditis [2]. 
Here, we report a case with S. epidermidis endocarditis 
with a fulminant course causing major therapeutic prob-
lems because of emerging resistance to antibiotic therapy.
Case Report
A previously healthy 29-year-old man was admitted to our hos-
pital for elective cardiac surgery of a myxoma located on the 
anterior mitral leaflet. The mitral valve was reconstructed using 
xenopercardium as well as an anuloplasty ring. On the 5th postop-
erative day the patient developed fever up to 39.5 °C and a non-
productive cough. A transesophageal echocardiography (TEE) 
revealed no vegetations. After blood cultures were drawn, assum-
ing a pneumonia, cefepime 2 g bid intravenously (iv) was started 
on the 5th postoperative day. No catheter had been in place at the 
time of the first fever episode. Teicoplanin 800 mg qd iv was added 
to cefepime on the 6th postoperative day when CoNS grew in 
the blood cultures. A second set of blood cultures drawn prior to 
teicoplanin grew CoNS again raising the suspicion of postopera-
tive endocarditis. The resistance patterns of the first and second 
CoNS were different (Table 1). All CoNS isolates were identified 
as S. epidermidis. Therefore, the antibiotic therapy was switched 
to vancomycin 1 g bid iv and rifampin 450 mg bid po according 
to susceptibility testing on the 11th postoperative day. No growth 
was reported in subsequently drawn blood cultures.
Over the following days, despite adequate vancomycin 
trough levels (8.9–10.1 mg/l), the patient showed progressive heart 
failure. TEE was repeated on day 21 after surgery and revealed 
multiple vegetations and a perforation of the anterior mitral valve 
leaflet. Because of rapidly progressive heart failure, immediate 
reoperation was necessary. The vegetations and the anuloplasty 
ring were removed and the mitral valve was again reconstructed. 
CoNS could be isolated from the tissue samples and were identi-
fied as S. epidermidis. Notably, using pulsed-field gel electropho-
resis [3], the banding pattern of all isolates (i.e. from blood and 
tissue samples) was identical pointing to their genetic relatedness. 
Strikingly, susceptibility testing performed by disk diffusion on 
Mueller-Hinton agar at 35 °C according to the National Com-
mittee for Clinical Laboratory Standards (NCCLS) revealed new 
rifampin resistance (Table 1). In addition, minimal inhibitory 
concentrations (MIC) were determined by Etest® (AB Biodisk, 
Solna, Sweden) according to the manufacturer’s instructions. An-
tibiotic therapy was changed to vancomycin 1 g bid iv, quinupris-
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tinum/dalfopristinum 500 mg tid iv and levofloxacin 500 mg bid 
po for additional 6 weeks. The remainder of the clinical course 
was favorable. 
Discussion
This case report shows that similar to S. lugdunensis, S. epi-
dermidis can also cause rapidly progressive and destructive 
endocarditis, requiring surgery and antibiotics for success-
ful treatment. Despite adequate antibiotic therapy, resis-
tance in CoNS may emerge and lead to treatment failure. 
Recently, seven cases of native valve endocarditis due to S. 
epidermidis were reported of which three showed an acute 
course [4]. All seven patients needed cardiac surgery with 
valve replacement. Microscopic examinations of the valves 
showed gram-positive cocci and six of seven tissue speci-
mens grew S. epidermidis. Similar to our case, eradication 
was found to be difficult and required a combination of 
surgery and antibiotics. However, in contrast to our experi-
ence, antibiotic resistance did not emerge in that case se-
ries [4]. Recently, a report on 99 patients with native valve 
endocarditis due to CoNS was published [5]. Patients with 
native valve endocarditis due to CoNS had rates of heart 
failure and mortality similar to patients with native valve 
endocarditis due to Staphylococcus aureus. The proportion 
of patients requiring cardiac surgery was higher for native 
valve endocarditis due to CoNS compared to S. aureus. The 
frequent need for surgery had already been noted previ-
ously in a series of 21 patients with native valve endocar-
ditis due to CoNS [6].
S. epidermidis is capable of forming thick and multilay-
ered biofilms, especially in the presence of foreign bodies. 
Bacteria in biofilms show much slower growth rates than 
in their planktonic form [7]. These physiological factors 
render antibiotics, such as -lactam antibiotics and glyco-
peptides, which target metabolically active bacteria, much 
less active. The biofilm also hinders the immune system to 
display its full armamentarium by limiting access of phago-
cytic cells to pathogenic bacteria [8, 9]. 
Optimal antibiotic therapy of infections caused by 
CoNS is further complicated by the difficulty to precisely 
determine the susceptibility of these bacteria to glycopep-
tides by agar disk diffusion assays. The large glycopeptide 
molecules diffuse only poorly in agar. Thus the relevant 
zones of inhibition in disk assays remain small and diffi-
cult to interpret [10]. The poor correlation between the 
obtained zone diameters and the MIC often leads to incor-
rect interpretation [11]. Therefore, determination of MIC 
of glycopeptides against CoNS is recommended in patients 
with complicated CoNS bacteremia. The isolate in our case 
initially was considered susceptible to vancomycin and tei-
coplanin based on MIC determinations. After prolonged 
glycopeptide therapy, the isolates showed a higher MIC for 
teicoplanin. It is well known that isolates with decreased 
susceptibility to glycopeptides (especially to teicoplanin) 
can be selected in vitro and in vivo by exposure to glyco-
peptides [12].  
Nevertheless, even the MICs for glycopeptides must 
be interpreted cautiously since strains considered suscep-
tible according to the NCCLS may de facto be resistant 
to glycopeptide therapy. Peck et al. [13] reported S. epi-
dermidis strains, which were susceptible to vancomycin in 
the planktonic form (MIC: 3.1 mg/l; MBC 6.3 mg/l) but 
showed tolerance when tested sessile in a biofilm (MIC: 
3.1 mg/l; MBC > 400 mg/l), indicating that vancomycin may 
not efficiently kill the sessile bacteria in biofilms even at 
concentrations far above the MIC [13, 14].
Rifampin is the single most active agent against bio-
film-producing S. epidermidis, but resistant mutants can 
be readily selected with monotherapy. Mutations within 
rpoB (which encodes the -subunit of the RNA poly-
merase) can arise at frequencies of around 10-8 and may 
result in different levels of resistance to rifampin in the 
studied bacterial populations [15]. The whole population 
of susceptible bacteria will be replaced by a resistant sub-
population following exposure to rifampin. Since only 
approximately 106 cfu/ml are used for conventional MIC 
Isolates  Vancomycin   Teicoplanin  Rifampin  Oxacillin  Gentamicin  Levofloxacin  Linezolid  Quinupristin/
 MIC MIC MIC MIC MIC MIC MIC dalfopristin
        MIC
 S1: ≤ 4 mg/l S: ≤ 8 mg/l S: ≤ 1 mg/l S:  0.25 mg/l S: ≤ 4 mg/l S: ≤ 2 mg/l S: ≤ 4 mg/l S: ≤ 1 mg/l 
 I2: 8-16 mg/l I: 16 mg/l I: 2 mg/l R: 0.5 mg/l I: 8 mg/l I: 4 mg/l  I: 2 mg/l  
 R3: ≥ 32 mg/l R: ≥ 32 mg/l R: ≥ 4 mg/l  R: ≥ 16 mg/l R: ≥ 8 mg/l  R: ≥ 4 mg/l
A4 2 6 ≤ 0.016 128 0.5 0.38 2
B5 3 12 ≤ 0.016 > 256 > 256 0.125 1.5
C6 3 32 > 256 32 > 256 0.125 1 0.19 
S1: sensitive against the tested drug; I2: intermediate resistance against the tested drug; R3: resistance against the tested drug; strain A4:  
blood culture 5th postoperative day;  strain B5: blood culture 6th postoperative day; strain C6: valve tissue sample
Table 1
Minimal inhibitory concentrations (MIC) of the three S. epidermidis strains (E-test).
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determinations, this method may not detect the natu-
rally occurring resistant variants in a population. On the 
other hand, high cell densities exceeding 108 cfu/ml may 
be found in biofilms [16], raising the possibility that ri-
fampin-resistant bacteria may already be present in this 
situation at the onset of treatment. 
In our case, the relatively high MICs for glycopeptide 
antibiotics taken together with the diminished efficiency 
of these antibiotics in biofilms, and the high bacterial load 
in endocarditis may have contributed to treatment failure 
with the documented development of rifampicin resistance. 
The banding pattern of all isolated S. epidermidis isolates 
was indistinguishable in pulsed-field gel electrophoresis 
(PFGE), indicating that they were identical despite the dif-
ferent antibiotic resistance patterns found. The differences 
in aminoglycoside resistance are most likely due to changes 
in plasmid content as described previously [17].
In the presented case, treatment consisting of quinu-
pristin/dalfopristin, levofloxacin, and vancomycin after 
surgical removal of the vegetations and the anuloplasty 
ring proved to be successful. Quinupristin/dalfopristin is 
the first semisynthetic injectable streptogramin antibiotic 
available and a promising alternative to glycopeptides for 
the treatment of many multiresistant gram-positive bacte-
ria. Quinupristin/dalfopristin has a greater bactericidal ef-
fect on CoNS in biofilms than flucloxacillin, glycopeptides, 
erythromycin, and ciprofloxacin [18]. 
In conclusion, S. epidermidis can cause rapid valve de-
struction resulting in heart failure and a combination of sur-
gery and antibiotic therapy may be necessary. In our case, 
the surgical removal of the infected tissue alone might have 
been sufficient for the favorable outcome. Blood cultures 
positive for S. epidermidis must be interpreted carefully in 
high-risk patients, endocarditis should be excluded and ad-
equate resistance testing performed. Combination therapy 
with vancomycin and rifampin must be used with caution 
because high bacterial loads in endocarditis together with 
low efficiency of antibiotics within biofilms may readily se-
lect for rifampin-resistant clones. 
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